A Phase 1 interventional study of DNL628 and Placebo in Alzheimer Disease, Early Onset, sponsored by Denali Therapeutics Inc.. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Denali Therapeutics Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies in Alzheimer Disease with a site in Netherlands — 16 open to participants now, 27 under way, 9 of them phase 3. Alzheimer Disease · Netherlands.
Among the 133 studies in Alzheimer Disease with a site in Netherlands, this one is the 82nd largest by planned enrollment of the 119 interventional ones that give a count, is one of 4 that started in 2026, is one of 22 in phase 1, reaches primary completion later than 10 of the 26 other live ones, and was the 132nd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →16 of the 133 studies in Alzheimer Disease with a site in Netherlands are open now. Recruiting first, the newest first:
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Netherlands, Australia, Austria and 14 more countries
Ages 18+
Alnylam Pharmaceuticals · Sites in Netherlands, Canada, Spain and 1 more country
Ages 40–80
Alzheimercentrum Amsterdam · Sites in Netherlands
Ages 55+
Bristol-Myers Squibb · Sites in Netherlands, United States, Argentina and 14 more countries
Ages 60–85
Merck Sharp & Dohme LLC · Sites in Netherlands, United States, Argentina and 8 more countries
Ages 50–85
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 45 · Phase 3 47 · Phase 4 1
First in 2000; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 68 is close to the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 241 across the 119 interventional studies, 502 across the 14 observational. Of the 99 that completed or were terminated, 45 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 133 have an industry lead sponsor. The 10 most frequent:
Denali Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Denali Therapeutics Inc. has 3 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Alzheimer Disease with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891716AC Immune SA[18F]ACI-19626 PET in TDP-43 Proteinopathies | 2026-11 |
| NCT07680335Alzheimercentrum AmsterdamThe BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease | 2026-12-31 |
| NCT03507257Indiana UniversityLongitudinal Early-onset Alzheimer's Disease Study Protocol | 2027-01-01 |
| NCT07328451Denali Therapeutics Inc.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease | 2027-02 |
| NCT07234942Hoffmann-La RocheA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 133 studies in Alzheimer Disease with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment, or mild AD with biomarker evidence of amyloid positivity.
Note: In the Netherlands, this study includes an open-label extension.
Key Inclusion Criteria:
Have AD severity defined as the following at screening:
Key Exclusion Criteria:
Have had previous anti amyloid or anti tau immunotherapy (including active immunization)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DNL628
Drug: Placebo
Multiple ascending doses
Multiple ascending doses
Incidence and severity of treatment-emergent adverse events (TEAEs) throughout the double-blind period
Time frame: 37 weeks
PK parameter: Maximum concentration (Cmax) of DNL628 in plasma
Time frame: 37 weeks
PK Parameter: Time to reach maximum concentration (tmax) of DNL628 in plasma
Time frame: 37 weeks
PK Parameter: Minimum concentration (Cmin) of DNL628 in plasma
Time frame: 37 weeks
PK Parameter: Area under the concentration-time curve (AUC) from time zero to time of last measurable concentration (AUClast) of DNL628 in plasma
Time frame: 37 weeks
PK Parameter: AUC from time 0 to the end of the dosing interval (AUCτ) of DNL628 in plasma
Time frame: 37 weeks
PK Parameter: terminal elimination half-life (t1/2) of DNL628 in plasma
Time frame: 37 weeks
PK Parameter: Accumulation ratio of DNL628 in plasma
Time frame: 37 weeks
Change from baseline in total tau and ptau181 as measured in CSF
Time frame: 25 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Feb 2027, 13 months after the start.
Of 163 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 13 months is close to that.
Counting every sponsor, half of 236 studies reached it within 17 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Denali Therapeutics Inc.